CVS Stock Surges On Huge Q1 Beat Amid GLP-1 Deal With Novo Nordisk
In This Article:
CVS Health blew past first-quarter earnings estimates early Thursday, while raising its full-year outlook by a smaller amount. The pharmacy and health benefits giant also announced an agreement to make Novo Nordisk's Wegovy its preferred GLP-1 obesity medication. CVS stock is sharply higher, while NVO also jumped in early stock market action.
Terms and Privacy Policy